

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CHANGE OF NAME
CONVEYING PARTY DATA	
Name	Execution Date
VERENIUM CORPORATION	03/26/2012
RECEIVING PARTY DATA	
Name:	DSM IP ASSETS B.V.
Street Address:	Het Overloon 1
City:	Heerlen
State/Country:	NETHERLANDS
Postal Code:	6411 TE
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	13103276
Application Number:	13058584
CORRESPONDENCE DATA	
Fax Number:	(202)220-2213
Phone:	2025083400
Email:	mailroomdc@bakerdonelson.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	Baker Donelson Bearman Caldwell & Berk
Address Line 1:	920 Massachusetts Avenue
Address Line 2:	Suite 900
Address Line 4:	Washington, DC, DISTRICT OF COLUMBIA 20001
ATTORNEY DOCKET NUMBER:	2919208-000001
NAME OF SUBMITTER:	Susan E. Shaw McBee
Total Attachments: 13 source=Assignment_and_Schedule#page1.tif	

CH \$80.00 13103276

source=Assignment_and_Schedule#page2.tif
source=Assignment_and_Schedule#page3.tif
source=Assignment_and_Schedule#page4.tif
source=Assignment_and_Schedule#page5.tif
source=Assignment_and_Schedule#page6.tif
source=Assignment_and_Schedule#page7.tif
source=Assignment_and_Schedule#page8.tif
source=Assignment_and_Schedule#page9.tif
source=Assignment_and_Schedule#page10.tif
source=Assignment_and_Schedule#page11.tif
source=Assignment_and_Schedule#page12.tif
source=Assignment_and_Schedule#page13.tif



www.verenium.com

4955 Directors Place, San Diego, CA 92121
800.523.2990

FOR IMMEDIATE RELEASE

VERENIUM COMPLETES \$37 MILLION SALE OF CERTAIN ASSETS TO DSM

-- Strategic transaction demonstrates value of products and technology --

-- Company to host conference call at 4:30 p.m. ET today --

SAN DIEGO, CA., March 26, 2012 – Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced it has closed a transaction with DSM Food Specialties B.V., a business group of Royal DSM, in which Verenium has sold to DSM its Oilseed Processing business, licensed certain enzymes for use in the food and beverage markets, and will provide access to new gene libraries to be developed by Verenium. Verenium will receive \$37 million in total consideration, including transaction and related expenses, on Monday, March 26, 2012.

"This agreement is a further example of the substantial value industry-leading companies place on our unique products and capabilities," said James Levine, President and Chief Executive Officer at Verenium. "Moving forward, Verenium remains committed to realizing the growth potential from our commercial and pipeline products, and using our proprietary technology to create new and valuable products."

Following the transaction, Verenium's business remains focused on providing novel enzymes in the areas of animal health and nutrition, grain processing and oilfield services. In addition, Verenium's robust pipeline of novel product candidates provides an important basis for future growth.

Transaction Terms

Key terms of the agreement between the companies include:

- DSM has acquired Verenium's oilseed processing enzymes, including Purifine[®] PLC, product candidates, and the intellectual property covering these products and product candidates for use in the oilseed processing market. In addition, DSM has assumed Verenium's existing oilseed processing customers and the Company's partnership agreements with Bunge, Alfa Laval and Desmet Ballestra.
- Verenium has granted DSM exclusive licenses to its alpha-amylase and xylanase enzyme products for use in the food and beverage markets. Verenium retains certain rights to these products in markets outside of the food and beverage markets.
- Verenium and DSM have entered into a supply agreement for Verenium to manufacture the Purifine[®] PLC, alpha-amylase and xylanase products for DSM.
- Verenium will develop new gene libraries for use by DSM. Both companies will have full access to the libraries for the purpose of identifying new product opportunities. This transaction does not impact Verenium's existing gene libraries.
- The products acquired by DSM represented approximately \$7.5 million in revenue to Verenium in 2011.

Intellectual Property Deed of Assignment

This Intellectual Property Deed of Assignment (the "Assignment") is made as of this 23rd day of March 2012 by and between Verenum Corporation., a corporation organized and existing under the laws of the State of Delaware ("Company"); and DSM Food Specialties B.V., a private company organized and existing under the laws of the Kingdom of the Netherlands ("Purchaser"). Reference is made herein to the Asset Purchase Agreement, dated March 23, 2012 (the "Agreement"). Capitalized terms used but not defined herein shall have the meanings assigned to such terms in the Agreement.

The Company hereby sells, assigns, transfers and sets over to Purchaser the entire right, title and interest of Company in and to all of the Transferred Intellectual Property, for Purchaser's own use and enjoyment (but subject to the provisions of the Agreement and the Ancillary Agreements), and for the full use and enjoyment (but subject to the provisions of the Agreement and the Ancillary Agreements) of Purchaser's successors, assigns or other legal representatives, as fully and entirely (but subject to the provisions of the Agreement and the Ancillary Agreements) as the same would have been held and enjoyed by the Company if the Agreement had not been made.

The Company shall provide Purchaser and its successors, assigns or other legal representatives, commercially reasonable cooperation and assistance at Purchaser's reasonable request and expense, including, if appropriate and reasonably capable of being performed by the Company, using commercially reasonable efforts to execute or cause to be executed affidavits, declarations, oaths, exhibits, assignments, powers of attorney or other documentation that may be reasonably required: (1) in the preparation and prosecution of any application for registration or any application for renewal of a registration governing any Transferred Intellectual Property; (2) in the prosecution or defense of any interference, opposition, infringement or other proceedings that may arise in connection with the Transferred Intellectual Property, including testifying as to any facts relating to the Transferred Intellectual Property assigned herein and this Assignment; (3) in obtaining any additional protection for the Transferred Intellectual Property that Purchaser may deem appropriate which may be secured under the laws of any jurisdiction; and (4) in the implementation or perfection of this Assignment.

Remainder of page intentionally left blank

IN WITNESS WHEREOF, the parties have caused their duly authorized representatives to execute this Assignment as of the date first written above.

VERENIUM CORPORATION

By: James Levine
James Levine
CEO

DSM FOOD SPECIALTIES B.V.

By: _____
Hans Christian Ambjerg
Director

By: _____
Hugh Welsh
President DSM NA

[Signature Page to Intellectual Property Deed of Assignment]

IN WITNESS WHEREOF, the parties have caused their duly authorized representatives to execute this Assignment as of the date first written above.

VERENIUM CORPORATION

By: _____
James Levine
CEO

DSM FOOD SPECIALTIES B.V.

By: _____
Hans Christian Ambjerg
Director

By: _____
Hugh Welsh
President DSM NA

Signature Page to Intellectual Property Deed of Assignment

PATENT
REEL: 028173 FRAME: 0517

Schedule 2.1(c)

SYT	Family Name	Type	Owner	Case Number	Country	Application Status	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Issue Date
Y	Esterase	Patent	Verenium	D1180-2US	US	Granted	09/903,410	10-Jul-2001			7,288,400	30-Oct-2007
Y	Esterase	Patent	Verenium	D1180-8EPD1	EP	Published	10001560.1	16-Feb-2010				
Y	Phospholipase C	Patent	Verenium	D1250-1AM	AM	Granted		21-Apr-2003			010903	29-Aug-2008
Y	Phospholipase C	Patent	Verenium	D1250-1AU	AU	Granted	2003243157	13-Oct-2004	2003243157	20-Mar-2008	2003243157	03-Jul-2008
Y	Phospholipase C	Patent	Verenium	D1250-1AUD1	AU	Pending	2008201667	21-Apr-2003				
Y	Phospholipase C	Patent	Verenium	D1250-1AZ	AZ	Granted		21-Apr-2003			010903	29-Aug-2008
Y	Phospholipase C	Patent	Verenium	D1250-1BR	BR	Published	P10309391-3	21-Apr-2003		25-Oct-2005		
Y	Phospholipase C	Patent	Verenium	D1250-1BY	BY	Granted		21-Apr-2003			010903	29-Aug-2008
Y	Phospholipase C	Patent	Verenium	D1250-1CA	CA	Published	2,481,411	21-Apr-2003	2481411	30-Oct-2003		
Y	Phospholipase C	Patent	Verenium	D1250-1CN	CN	Published	03813594.9	21-Apr-2003	CN1659276A	24-Aug-2005		
Y	Phospholipase C	Patent	Verenium	D1250-1CND1	CN	Published	2011100549 72.5	07-Mar-2011	CN 102174546A	07-Sep-2011		

SYT	Family Name	Type	Owner	Case Number	Country	Application Status	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Issue Date
Y	Phospholipase C	Patent	Verenium	D1250-1EA	EA	Granted	2004 01407	21-Apr-2003	2004 01407	24-Feb-2006	010903	29-Aug-2008
Y	Phospholipase C	Patent	Verenium	D1250-1EP	EP	Published	03747055.6	21-Apr-2003	EP1497418	19-Jan-2005		
Y	Phospholipase C	Patent	Verenium	D1250-1EPD1	EP	Published	10180847.5	21-Apr-2003	2298871	23-Mar-2011		
Y	Phospholipase C	Patent	Verenium	D1250-1IND1	IN	Pending	5094/KOLNP/2007	23-Oct-2007				
Y	Phospholipase C	Patent	Verenium	D1250-1KG	KG	Granted		21-Apr-2003			010903	29-Aug-2008
Y	Phospholipase C	Patent	Verenium	D1250-1KZ	KZ	Granted		21-Apr-2003			010903	29-Aug-2008
Y	Phospholipase C	Patent	Verenium	D1250-1MD	MD	Granted		21-Apr-2003			010903	29-Aug-2008
Y	Phospholipase C	Patent	Verenium	D1250-1RU	RU	Granted		21-Apr-2003			010903	29-Aug-2008
Y	Phospholipase C	Patent	Verenium	D1250-1TJ	TJ	Granted		21-Apr-2003			010903	29-Aug-2008
Y	Phospholipase C	Patent	Verenium	D1250-1TM	TM	Granted		21-Apr-2003			010903	29-Aug-2008
Y	Phospholipase C	Patent	Verenium	D1250-2AU	AU	Granted	2005221136	18-Sep-2006			2005221136	27-May-2011
Y	Phospholipase C	Patent	Verenium	D1250-2AUD1	AU	Pending	2011218662	08-Mar-				

SYT	Family Name	Type	Owner	Case Number	Country	Application Status	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Issue Date
								2005				
Y	Phospholipase C	Patent	Verenium	D1250-2BR	BR	Published	PI05085559-4	08-Mar-2005		14-Aug-2007		
Y	Phospholipase C	Patent	Verenium	D1250-2CA	CA	Published	2,559,060	08-Sep-2006	2,559,060			
Y	Phospholipase C	Patent	Verenium	D1250-2CN	CN	Published	2005800146 67.6	07-Nov-2006	101426918	06-May-2009		
Y	Phospholipase C	Patent	Verenium	D1250-2D1	US	Granted	11/625,765	22-Jan-2007	09-0053191	26-Feb-2009	7943360	17-May-2011
Y	Phospholipase C	Patent	Verenium	D1250-2D2	US	Pending	13/090,682	20-Apr-2011				
Y	Phospholipase C	Patent	Verenium	D1250-2EP	EP	Published	05727242.9	08-Mar-2005	1748954	07-Feb-2007		
Y	Phospholipase C	Patent	Verenium	D1250-2IN	IN	Pending	2893/KOLNP /2006	06-Oct-2006				
Y	Phospholipase C	Patent	Verenium	D1250-2IND1	IN	Pending	612/KOL/20 11	02-May-2011				
Y	Phospholipase C	Patent	Verenium	D1250-2JP	JP	Published	2007-502990	08-Mar-2006	2007531516	08-Nov-2007		
Y	Phospholipase C	Patent	Verenium	D1250-2JPD1	JP	Published	2007-087917	08-Mar-2005	2011-172583	08-Sep-2011		
Y	Phospholipase C	Patent	Verenium	D1250-2N	US	Granted	10/592,450	29-Jul-2008	08-0317731	25-Dec-2008	7,977,080	12-Jul-2011
Y	Phospholipase C	Patent	Verenium	D1250-2US	US	Granted	10/796,907	08-Mar-2004	050108789	19-May-2005	7,226,771	05-Jun-2007

SYT	Family Name	Type	Owner	Case Number	Country	Application Status	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Issue Date
Y	Phospholipase C	Patent	Verenium	D1250-3AU	AU	Allowed	20055264938	20-Dec-2006				
Y	Phospholipase C	Patent	Verenium	D1250-3AUD1	AU	Pending		14-Feb-2012				
Y	Phospholipase C	Patent	Verenium	D1250-3BR	BR	Published	P10510939-6	18-Dec-2006		17-Jul-2007		
Y	Phospholipase C	Patent	Verenium	D1250-3CA	CA	Published	2,570,872	15-Dec-2006	2570872			
Y	Phospholipase C	Patent	Verenium	D1250-3CN	CN	Published	200580027938.1	15-Feb-2007	1014322292	13-May-2009		
Y	Phospholipase C	Patent	Verenium	D1250-3EA	EA	Granted	2007 00032	15-Jan-2007			013993	30-Aug-2010
Y	Phospholipase C	Patent	Verenium	D1250-3EP	EP	Published	05762779.6	14-Jun-2005	1791853	06-Jun-2007		
Y	Phospholipase C	Patent	Verenium	D1250-3EPD1	EP	Pending	12150400.5	14-Jun-2005				
Y	Phospholipase C	Patent	Verenium	D1250-3IN	IN	Pending	146/KOLNP/2007	11-Jan-2007				
Y	Phospholipase C	Patent	Verenium	D1250-3JP	JP	Published	2007-516623	18-Dec-2006	08-505619	28-Feb-2008		
Y	Phospholipase C	Patent	Verenium	D1250-3ND1	US	Published	13/103,276	09-May-2011	US 2011 0306117 A1	15-Dec-2011		
Y	Phospholipase C	Patent	Verenium	D1250-5AR	AR	Pending	07 01 04194	21-Sep-2007				
Y	Phospholipase C	Patent	Verenium	D1250-	BR	Pending	P10716872-1	19-				

SYT	Family Name	Type	Owner	Case Number	Country	Application Status	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Issue Date
				5BR				Mar-2009				
Y	Phospholipase C	Patent	Verenium	D1250-5CA	CA	Pending	2,663,001	10-Mar-2009				
Y	Phospholipase C	Patent	Verenium	D1250-5CN	CN	Published	2007800429 83.3	20-May-2009	101558154			
Y	Phospholipase C	Patent	Verenium	D1250-5EA	EA	Granted	200970308	20-Apr-2009			015591	31-Oct-2011
Y	Phospholipase C	Patent	Verenium	D1250-5EP	EP	Published	07853585.3	05-Mar-2009		13-May-2009		
Y	Phospholipase C	Patent	Verenium	D1250-5IN	IN	Pending	971/KOLNP/ 2009	13-Mar-2009				
Y	Phospholipase C	Patent	Verenium	D1250-5KR	KR	Pending	10-2009- 7008152	21-Apr-2009				
Y	Phospholipase C	Patent	Verenium	D1250-5MX	MX	Pending	MX/a/2009/ 003034	20-Mar-2009				
Y	Phospholipase C	Patent	Verenium	D1250-5N	US	Published	12/442,255	13-Jan-2010	20110093965	21-Apr-2011		
Y	Phospholipase C	Patent	Verenium	D1250-5TH	TH	Pending	0701004778	21-Sep-2007				
Y	Phospholipase C	Patent	Verenium	D1250-6AR	AR	Pending	2010 01 03698	08-Oct-2010				
Y	Phospholipase C	Patent	Verenium	D1250-6WO	WO	Published	PCT/US2010 /51903	08-Oct-2010		21-Apr-2011		
Y	LIPASE	Patent	Verenium	D1430-	AU	Granted	2004277368	08-			2004277	05-May-

SYT	Family Name	Type	Owner	Case Number	Country	Application Status	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Issue Date
				2AU				Mar-2004			368	2011
Y	LIPASE	Patent	Verenium	D1430-2AUD1	AU	Pending	2011201719	08-Mar-2004				
Y	LIPASE	Patent	Verenium	D1430-2BR	BR	Published	PI0408157-9	06-Sep-2005		07-Mar-2006		
Y	LIPASE	Patent	Verenium	D1430-2CA	CA	Published	2,515,583	07-Sep-2005	2515583			
Y	LIPASE	Patent	Verenium	D1430-2CL	CL	Pending	2307-2005	07-Sep-2005				
Y	LIPASE	Patent	Verenium	D1430-2CO	CO	Granted	05101225	05-Oct-2005			12802	08-Mar-2004
Y	LIPASE	Patent	Verenium	D1430-2COD1	CO	Granted	05.101.225A	02-Jun-2010			12803	08-Mar-2004
Y	LIPASE	Patent	Verenium	D1430-2EP	EP	Published	04809311.6	23-Sep-2005	EP1601332	07-Dec-2005		
Y	LIPASE	Patent	Verenium	D1430-2JP	JP	Granted	2006-509241	08-Mar-2004			4829105	22-Sep-2011
Y	LIPASE	Patent	Verenium	D1430-2JPD1	JP	Published	2010-171845	30-Jul-2010	2010-284168	24-Dec-2010		
Y	LIPASE	Patent	Verenium	D1430-2MX	MX	Pending	PA/a/2005/009568	08-Mar-2004	2005009568	23-Feb-2006		
Y	LIPASE	Patent	Verenium	D1430-2N	US	Published	10/547,956	06-Sep-2005		30-Aug-2007		
Y	LIPASE	Patent	Verenium	D1430-	US	Published	11/575,066	09-	08-0305531	11-Dec-		

SYT	Family Name	Type	Owner	Case Number	Country	Application Status	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Issue Date
				3N				Nov-2007		2008		
Y	LIPASE	Patent	Verenium	D1430-4CA	CA	Published	2,601,472	07-Sep-2007	2601472			
Y	LIPASE	Patent	Verenium	D1430-4EP	EP	Published	06748332.1	08-Mar-2006	1869173	26-Dec-2007		
Y	LIPASE	Patent	Verenium	D1430-4N	US	Published	11/817,865	05-Sep-2007	090297495	03-Dec-2009		
N	Saturase	Patent	Verenium	D2280-2AR	AR	Pending	09 01 03327	28-Aug-2009				
N	Saturase	Patent	Verenium	D2280-2BR	BR	Pending		28-Feb-2011				
N	Saturase	Patent	Verenium	D2280-2CA	CA	Pending	2735230	28-Aug-2009				
N	Saturase	Patent	Verenium	D2280-2CN	CN	Published	2009801429 71.7	28-Aug-2009	CN 102197043A	21-Sep-2011		
N	Saturase	Patent	Verenium	D2280-2EA	EA	Pending	201170388	28-Aug-2009				
N	Saturase	Patent	Verenium	D2280-2EP	EP	Published	09810676.8	28-Aug-2009	2328907	08-Jun-2011		
N	Saturase	Patent	Verenium	D2280-2IN	IN	Published	774/KOLNP/ 2011	21-Feb-2011	774/KOLNP/20 11	13-May-2011		
N	Saturase	Patent	Verenium	D2280-2KR	KR	Pending	10-2011- 7007310	29-Mar-2011				

SYT	Family Name	Type	Owner	Case Number	Country	Application Status	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Issue Date
N	Saturase	Patent	Verenium	D2280-2MX	MX	Pending	MX/a/2011/002297	28-Aug-2009				
N	Saturase	Patent	Verenium	D2280-2N	US	Published	13/058,584	11-Feb-2011	US-2011-0277046-A1	10-Nov-2011		
N	Saturase	Patent	Verenium	D2280-2US	US	Allowed	12/202,119	29-Aug-2008	2010-0055085	04-Mar-2010		
N/A	PURIFINE	Trademark	Verenium	T8160-AR01	AR	TM-Registd	2971646	13-Jan-2010	2971646	31-Mar-2010	2404628	29-Oct-2010
N/A	PURIFINE	Trademark	Verenium	T8160-BO01	BO	Pending	SM-4545-2011	25-Aug-2011				
N/A	PURIFINE	Trademark	Verenium	T8160-BR01	BR	Pending	830520619	11-Jan-2010				
N/A	PURIFINE	Trademark	Verenium	T8160-CA01	CA	Pending	1,465,141	08-Jan-2010				
N/A	PURIFINE	Trademark	Verenium	T8160-CN01	CN	Pending	7997784	15-Jan-2010				
N/A	PURIFINE	Trademark	Verenium	T8160-CTM01	EM	TM-Registd	8799744	08-Jan-2010	8799744	15-Mar-2010	8799744	28-Jun-2010
N/A	PURIFINE	Trademark	Verenium	T8160-IN01	IN	TM-Pending	2193919	23-Aug-2011				
N/A	PURIFINE	Trademark	Verenium	T8160-KR01	KR	TM-Pending	40-2011-45591	22-Aug-2011				
N/A	PURIFINE	Trademark	Verenium	T8160-MX01	MX	TM-Pending	1205328	23-Aug-2011				
N/A	PURIFINE	Trademark	Verenium	T8160-PY01	PY	TM-Pending	35148	22-Aug-2011				

SYT	Family Name	Type	Owner	Case Number	Country	Application Status	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Issue Date
N/A	PURIFINE	Trademark	Verenium	T8160-TH01	TH	TM-Pending	817628	24-Aug-2011				
N/A	PURIFINE	Trademark	Verenium	T8160-US01	US	TM-Registd	78/564,145	09-Feb-2005			3308380	09-Oct-2007
N/A	PURIFINE	Trademark	Verenium	T8160-UY01	UY	TM-Pending	427457	21-Sep-2011				
N/A	purifine.com	Domain	Verenium									
N/A	purifine.us	Domain	Verenium									

SYT - A "y" in this column denotes that such Transferred Intellectual Property is subject to the license to Syngenta as described in Section 2.1 (c) of the Agreement.